GENFIT Announces NIS2+® as Instrumental Tool in New Clinical Practice Guidelines for MAFLD
Jun 17, 2024
Genfit Invest Information
FDA Grants Accelerated Approval to Ipsen and Genfit's Iqirvo for Liver Disease Treatment
Jun 12, 2024
GENFIT Reaches Historic FDA Approval with Ipsen's Iqirvo® for Primary Biliary Cholangitis
Jun 11, 2024
GENFIT Foresees Growth with Elafibranor Approvals for PBC Across US and Europe
Dec 9, 2023
GENFIT Announces Q3 2023 Financial Results with Cash Reserves and Revenue Insights
Nov 10, 2023
GENFIT Announces Third Quarter 2023 Financial Outcomes and Update on R&D Progress
Nov 10, 2023